bismuth quadruple therapy
PreclinicalSmall molecule
bismuth quadruple therapy is one of 11 small molecule programs targeting Peptic Ulcer Disease. It is currently in Preclinical.
1
Indications
6
Total Trials
3
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Peptic Ulcer Disease
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Aleve
Alnylam PharmaceuticalsApproved
Cytotec
PfizerApproved
Flagyl
DDePuy Orthopaedics
Approved
Levaquin
WWim Janssens
Approved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Prevacid
TakedaPreclinical
Aciphex
Akero TherapeuticsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Helicobacter Pylori1 trial
Peptic Ulcer Disease1 trial
Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease
Recruiting·—·N/A·NCT07260006·80 enrolled
Helicobacter Pylori Infection1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for bismuth quadruple therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details